Peel Hunt reissued their buy rating on shares of Silence Therapeutics (LON:SLN) in a research report report published on Tuesday morning.

Shares of Silence Therapeutics stock opened at GBX 150.75 ($1.94) on Tuesday. Silence Therapeutics has a 12-month low of GBX 71.88 ($0.93) and a 12-month high of GBX 254.75 ($3.29).

About Silence Therapeutics

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

Further Reading: Do Tariffs Work?

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.